非小细胞肺癌靶向治疗药物的研究进展

Advances in research on drugs targeting non-small cell lung cancer

目前非小细胞肺癌(NSCLC)是造成死亡最多的恶性肿瘤之一,大部分患者一经发现已是晚期且预后很差,但近十年来以化疗为主的治疗手段并未使非小细胞肺癌的疗效获得突破性进展。因此非小细胞肺癌分子靶向治疗成为研究的热点,分子靶向治疗药物包括:EGFR抑制剂、间变淋巴瘤激酶(ALK)抑制剂、抗血管生成药物、哺乳动物雷帕霉素靶蛋白(m TOR)抑制剂等,为非小细胞肺癌患者临床用药和非小细胞肺癌靶向治疗药物开发提供参考。本文将从这几类药物的作用机制、适用范围、药物疗效等作一综述。

At present, non-small cell lung canc- er（NSCLC） is one of the malignant tumors with the highest mortality rates. Most NSCLC cases often have incurable locally advanced or metastatic disease at the time of diagnosis and the average prognosis still remains unsatisfactory. Over the past 10 years, how- ever, chemotherapy, as a first-line therapy, has failed to progress in terms of curative effects against NSCLC. So molecular targeted therapy has recently become a focus of study for non-small cell lung canc- er. The drugs for molecular targeted therapy mainly include EGFR tyrosine kinase inhibitors, ALK inhib-itors, Anti-angiogenesis drugs, and roTOR inhibitors. These drugs provide the reference for clinical medi- cation and targeted therapy drug development of NSCLC. In this article, the progress in targeted therapy for NSCLC is introduced based on three aspects： mechanism of drug action, applicable people, and drug efficacy.